impossible to predict such stocks and how they go. little revenue is the main concern and 200x revenue. stock is impossible to derive a valuation of with such revenues. potential is hard to be classified without any real traction so far as evidenced by the revenue. re their medicine technique is impossible to really understand, i am not sold on the science and whether there will be takeup of it. a lot of these new ipo's are not very high quality like in past years, no real ebitda or no growth.
